"Lopinavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.
| Descriptor ID |
D061466
|
| MeSH Number(s) |
D03.383.742.698.553
|
| Concept/Terms |
Lopinavir- Lopinavir
- N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
|
Below are MeSH descriptors whose meaning is more general than "Lopinavir".
Below are MeSH descriptors whose meaning is more specific than "Lopinavir".
This graph shows the total number of publications written about "Lopinavir" by people in this website by year, and whether "Lopinavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lopinavir" by people in Profiles.
-
Squires KE, Johnson M, Yang R, Uy J, Sheppard L, Absalon J, McGrath D. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother. 2011 Feb; 66(2):363-70.
-
Castelnuovo B, John L, Lutwama F, Ronald A, Spacek LA, Bates M, Kamya MR, Colebunders R. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic). 2009 Jan-Feb; 8(1):52-9.
-
Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008 Aug 12; 52(7):569-76.
-
van den Berg-Wolf M, Klibanov OM, Gaughan JP, Tedaldi EM. Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients. AIDS Patient Care STDS. 2008 Jun; 22(6):483-8.